Mota Luiz Alberto Alves, Melo Marília Silvino Iglésias, Santos Maria Heloísa Pedrosa, de Albuquerque Kátia Maria Gomes, Tavares Cristiana de Lima
Hospital Universitário Oswaldo Cruz.
Rev Assoc Med Bras (1992). 2007 Jul-Aug;53(4):370-3. doi: 10.1590/s0104-42302007000400026.
To evaluate the clinic and audiometric evolution of individuals who underwent chemotherapy with cisplatin.
Four volunteers, all women, between 38 and 69 years of age were descriptively evaluated. All did otorinolaryngoiatric exam and audiometric evaluation with tonal and speech audiometric and impedance tests before and after treatment with cisplatin. In addition, all were subjectively evaluated pre- and post-chemotherapy by a questionnaire.
One volunteer did not present auditory disorders. Three volunteers presented bilateral hearing loss, mild to moderate in 6 kHz and 8 kHz frequencies, after chemotherapy with cisplatin. All volunteers who developed hearing loss after treatment also presented tinnitus.
Since cisplatin is considered ototoxic, all individuals undergoing chemotherapy with this drug must be submitted to audiometric monitoring for early diagnosis of a hearing loss.
评估接受顺铂化疗的个体的临床和听力变化情况。
对4名年龄在38至69岁之间的女性志愿者进行描述性评估。所有志愿者在顺铂治疗前后均进行了耳鼻喉科检查以及纯音听力测试、言语听力测试和声阻抗测试的听力评估。此外，所有志愿者在化疗前后均通过问卷调查进行主观评估。
1名志愿者未出现听觉障碍。3名志愿者在接受顺铂化疗后出现双侧听力损失，在6千赫兹和8千赫兹频率处为轻度至中度。所有在治疗后出现听力损失的志愿者也都出现了耳鸣。
由于顺铂被认为具有耳毒性，所有接受该药物化疗的个体都必须接受听力监测，以便早期诊断听力损失。
